Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of AVT-02 UE ointment versus placebo in mild to moderate psoriasis vulgaris
2008-002765-31Phase 2Completed
- Sponsor
- Avontec
- Start
- May 2008
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AVT-02 UE ointment in plaque psoriasis, sponsored by Avontec. Primary endpoint: SOS50 response rate at week 4. Started May 2008; status: completed.
02
Drugs
AVT-02 UE ointment
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2008-002765-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002765-31.